3.3. pathology. 3.3.1. handling transurethral resection cystectomy specimens transurethral resection (tur), specimen tumour normal looking bladder wall taken, possible. specimens taken superficial deep areas tumour sent pathology laboratory separately, case outcome impact treatment decisions. random biopsies flat mucosa taken, biopsy specimen flat mucosa submitted separately . sampling sites must recorded urologist; pathologist report include location tumour tissue cystectomy specimen. anatomical tumour location relevant staging prognosis . rc, bladder fixation must carried soon possible. pathologist must open specimen urethra bladder dome fix specimen. female cystectomy specimen, length urethral segment removed en bloc specimen checked, preferably urological surgeon . specimen handling follow general rules published collaborative group pathologists urologists . must stressed may difficult confirm presence neoplastic lesion using gross examination cystectomy specimen tur chemotherapy, entire retracted ulcerated area inked included fixation. compulsory study urethra, ureters, prostate men radial margins . urethra-sparing cystectomy; level urethral dissection, completeness prostate, specifically apex (in men), inclusion entire bladder neck amount adjacent urethra, uterus vaginal vault (in women) documented pathologist. lymph node (ln) specimens provided totality, clearly labelled containers allow ptnm staging. case doubt adipose differentiation lns, entire specimen included. lymph nodes counted measured slides; capsular extension percentage ln invasion reported well vascular embols . case metastatic spread perivesical fat without real ln structures (capsule, subcapsular sinus), localisation nevertheless considered n+. potentially positive soft tissue margins inked pathologist evaluation . rare cases, fresh frozen sections may helpful determine treatment strategy . 3.3.2. pathology muscle-invasive bladder cancer mibc cases high-grade ucs. reason, prognostic information provided grading mibc . identification morphological subtypes important prognostic reasons treatment decisions [66-68]. data presented guidelines based 2004/2016 world health organization (who) classifications . update presented 2022 . currently following subtypes uc used : urothelial carcinoma (more 90% cases);urothelial carcinomas partial squamous and/or glandular divergent differentiation;micropapillary uc;nested/microcystic;large nested;microtubular uc;plasmacytoid, signet ring;lymphoepithelioma-like;giant cell, diffuse, undifferentiated;sarcomatoid uc;some ucs rare differentiations;urothelial carcinomas partial ne (neuroendocrine differentiation, % given);pure neuroendocrine carcinoma (including small large cell neuroendocrine carcinomas [chapter ne carcinomas genitourinary tract]). new 2022 subtypes considered hg . percentage subtype specimen must reported since shown prognostic value . majority subtypes mibc, 15–30% non-muscle invasive [73-80] (le: 3). 3.3.3. guidelines assessment tumour specimens recommendationsstrength ratingrecord depth invasion entire specimen (categories pt2a pt2b, pt3a pt3b pt4a pt4b).strongrecord margins special attention paid radial margin, prostate, ureter, urethra, peritoneal fat, uterus vaginal vault.record total number lymph nodes (lns), number positive lns extranodal spread.record lymphovascular invasion.record presence carcinoma situ.record sampling sites well information tumour size providing specimens pathologist. 3.3.4. eau-esmo consensus statements management advanced- variant bladder cancer * consensus statementbladder uc small cell neuroendocrine variant treated neoadjuvant chemotherapy followed consolidating local therapy.muscle-invasive pure scc bladder treated primary radical cystectomy lymphadenectomy.muscle-invasive pure adenocarcinoma bladder treated primary radical cystectomy lymphadenectomy.muscle-invasive small cell neuroendocrine variant bladder uc receive preventive brain irradiation avoid brain recurrence.differentiating urachal non-urachal subtypes adenocarcinoma essential making treatment decisions.t1 high-grade bladder urothelial cancer micropapillary histology (established complete turbt and/or re-turbt) treated immediate radical cystectomy lymphadenectomy. *only statements met priori consensus threshold across three stakeholder groups listed(defined ≥ 70% agreement ≤ 15% disagreement, vice versa).